The first cooperation project between Tianyan Pharmaceutical and Exelixis' original masked safe antibody conjugate drug has successfully reached a key milestone

On December 23, 2021, Tianyan Pharmaceuticals announced that the first cooperation project with Exelixis reached at the beginning of the year for a precision masking safe antibody conjugate drug (ADC) developed based on the core technology of Tianyan’s proprietary safe antibody (SAFEbody™) has been completed.
Successfully reached key milestones
.
According to the terms of the technical cooperation and licensing agreement signed in early 2021, after successfully obtaining the target safety antibody candidate drug for each cooperation project, Tianyan will receive a milestone payment of US$3 million
.
"We are very proud to be able to successfully screen Exelixis safe antibody drug candidates with precise masking function.
This cooperation further verifies the excellent performance of Tianyan's proprietary safe antibody SAFEbody core technology, and highlights the Tianyan Dynamic Precision Antibody Library (DPL).
) The unique advantages of the platform" said Dr.
Luo Peizhi, Chairman and CEO of Tianyan Pharmaceuticals, "In addition, with the clinical advancement of the ADG126 (anti-CTLA-4) safety antibody project of Tianyan, the core technology of the safe antibody SAFEbody will be provided with conclusive evidence.
The clinical verification also shows that the application of safe antibody technology has the potential to achieve a paradigm shift in the design and development of powerful therapeutic drugs such as antibody-conjugated drugs, thereby improving the clinical efficacy and quality of life of patients with debilitating diseases such as cancer.
" According to the terms of the agreement , Exelixis has paid $11 million in advance cooperation funds to Tianyan Pharmaceuticals in the early stage to develop safe antibody drug candidates for two targets.
In addition, Tianyan Pharmaceuticals will be matched with the progress of research and development and declaration for each target.
Milestone payments related to commercialization and commercialization, and net sales commissions for related products developed for each target
.
Tianyan’s safe antibody technology aims to cover the binding domain of antibodies through precise masking technology to overcome the safety and tolerability problems that exist in various antibody therapies in the past.
This will improve the tumor-specific targeting ability of antibodies, and at the same time The toxicity caused by binding to targets in non-tumor tissues is minimized, providing a brand-new solution to the long-standing challenges in the development of new drugs
.
In addition to empowering partners in the development of new drugs, Tianyan will also use safe antibody technology to build an internal highly differentiated and transformative product pipeline with both depth and breadth, including: anti-CTLA- which is about to complete the phase I dose ramp test.
4Safety antibody ADG126 and five IND-enabling projects, such as ADG153, the world’s first anti-CD47 safety antibody SAFEbody™ and ADG152 with a powerful tumor-killing antibody effector IgG1, fused with Tianyan A powerful CD20CD3 antibody generated by the proprietary bispecific CD3 T cell adaptor platform and safe antibody SAFEbody™ masking technology POWERbody™ With its unique artificial intelligence-driven antibody exploration and development platform, Tianyan creates a new tumor immunotherapy focused on The pipeline of transformative and innovative products, five antibodies are currently in the clinical development stage
.
About Tianyan Pharmaceutical Tianyan Pharmaceutical (NASDAQ: ADAG) is a platform-driven biopharmaceutical company in the clinical product development stage with independent platform output.
The company is committed to discovering and developing original antibodies as the cornerstone New cancer immunotherapy leverages computational biology and artificial intelligence.
With its trisomy platform technology (new epitope antibody NEObody™, safe antibody SAFEbody™ and powerful antibody POWERbody™), Tianyan Pharmaceuticals has established a focus on new tumors The unique and original antibody product line of immunotherapy, in order to solve the unmet clinical needs, Tianyan has reached a strategic partnership with a number of world-renowned partners, and has enabled its partners to develop new drugs with a variety of original cutting-edge technologies
.